Skip to content

Maintaining Investments in New Innovation Act

In committee: it can still change before the session ends.

US HR 1672 · House Bill · 119th Congress

Draft a letter
Stage
In committee
Started in
House
Sponsors
52
Latest action
Feb 27, 2025

What it does

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Official summary · Introduced in House · Feb 27, 2025

Titles and provisions can change as the bill moves.

Read the full textRead it on the official site

Where it stands

  1. Introduced (Done)

    Feb 27, 2025

  2. Committee (Current step)

    In committee · Feb 27, 2025

  3. Floor (Not started)

  4. Law (Not started)

What moved

Loading recorded actions…

Who is involved

Sponsors

The lawmakers who put their names on it, lead sponsors first.

Where it goes next

While a bill can still move, the questions are about people and money.

Work with this bill

Maintaining Investments in New Innovation Act | 52